文献速递类风湿关节炎系统性红斑狼疮脊柱关节炎

风湿病学中的抗肥胖药物:路在何方?

Antiobesity medications in rheumatology. Quo vadis?
PubMed 文献 · Ann Rheum Dis · 2025-09-13

肥胖是风湿与肌肉骨骼疾病(RMDs)中公认的合并症,脂肪组织通过免疫机制诱导低度炎症状态,因此抗肥胖药物在RMDs管理中的潜在作用日益受到关注。胰高血糖素样肽-1受体激动剂(GLP-1 RAs)最初获批用于2型糖尿病、肥胖及其心肾相关疾病,但越来越多证据表明其可能在RMDs背景下发挥免疫调节和抗炎作用。本文讨论GLP-1 RAs对骨关节炎、系统性红斑狼疮、类风湿关节炎、纤维肌痛和骨质疏松症等疾病的作用,强调正在进行的 promising 研究,并提出这些药物可用于难治性病例、RMDs高风险人群(如肥胖银屑病患者)或作为辅助治疗,同时考虑多数国家存在的费用障碍。初步发现令人鼓舞,但现有证据多限于小样本,需大规模随机对照试验评估长期安全性。

要点

  • GLP-1 RAs在RMDs中可能发挥免疫调节和抗炎作用,初步证据令人鼓舞。
  • 现有证据多限于小样本,需大规模随机对照试验评估长期安全性。
  • 作者提出GLP-1 RAs可用于难治性病例、RMDs高风险肥胖银屑病患者或作为辅助治疗。

核心结论

  • 初步发现令人鼓舞,但现有证据多限于小样本,需大规模随机对照试验评估这些药物在风湿病谱系中的长期安全性。
  • 作者提出这些药物可用于难治性病例、RMDs高风险人群(如肥胖银屑病患者)或作为辅助治疗,同时考虑多数国家的费用障碍。

研究设计与样本

  • 本文为观点文章,讨论当前关于GLP-1 RAs对骨关节炎、系统性红斑狼疮、类风湿关节炎、纤维肌痛和骨质疏松症等疾病作用的数据,并强调正在进行的 promising 研究。

主要发现

  • 脂肪组织通过免疫机制诱导低度炎症状态,抗肥胖药物在RMDs管理中的潜在作用日益受到关注。
  • GLP-1 RAs最初获批用于2型糖尿病、肥胖及其心肾相关疾病,但越来越多证据表明其可能在RMDs背景下发挥免疫调节和抗炎作用。

临床怎么用

  • 作者提出这些药物可用于难治性病例、RMDs高风险人群(如肥胖银屑病患者)或作为辅助治疗,同时考虑多数国家的费用障碍。

局限性

  • 现有证据多限于小样本。
  • 需大规模随机对照试验评估这些药物在风湿病谱系中的长期安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Obesity is a well-recognised comorbidity in the context of rheumatic and musculoskeletal diseases (RMDs), adversely affecting disease-related outcomes. Adipose tissue, through immunological mechanisms, induces a low-grade inflammatory state; as a result, there has been growing interest in evaluating the potential role of antiobesity drugs in the management of RMDs. Although they were initially approved for type 2 diabetes mellitus, obesity, and their cardiorenal associations, there is increasing evidence that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in particular may exert immunomodulatory and anti-inflammatory effects in the setting of RMDs. In this viewpoint, we discuss current data regarding the effects of GLP-1 RAs on several conditions, including osteoarthritis, systemic lupus erythematosus, rheumatoid arthritis, fibromyalgia, and osteoporosis. We also highlight ongoing studies, which appear to be promising. Furthermore, we propose that these drugs could be administered to difficult-to-manage cases or in people at an increased risk of developing RMDs (like obese psoriatic patients) or even as adjunctive therapy, considering also the cost barrier that exists in most countries. Preliminary findings are encouraging; however, as most of the available evidence is limited to a small sample size, large-scale randomised controlled trials are needed to evaluate also the long-term safety of these drugs throughout the spectrum of rheumatic disorders.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kyriazi N, Vassilakis KD, Bakiri A, et al. Antiobesity medications in rheumatology. Quo vadis? Ann Rheum Dis. 2025. PMID: 40946026. doi:10.1016/j.ard.2025.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。